Cempra shares rise a quarter on Phase III success

27 February 2017

American pharmaceutical company Cempra (Nasdaq: CEMP) has announced positive news from a Phase III study into oral fusidic acid for acute bacterial skin and skin structure infections (ABSSSI).

Fusidic acid was well tolerated in the study and achieved the primary endpoint, demonstrating non-inferiority against oral linezolid for early clinical response. The company's share price rose by a quarter following the news.

Cases of ABSSSI, which may be associated with an underlying disease such as diabetes, lead to more than five million hospitalizations in the USA and Europe each year.

Cempra will now meet with the US Food and Drug Administration to chart a regulatory course for the drug, which has been used in Europe for decades. The full results from the study will be submitted at an upcoming scientific forum.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK